Rational therapy for campylobacteriosis in children


DOI: https://dx.doi.org/10.18565/pharmateca.2019.10.40-44

K.D. Ermolenko (1), E.A. Martens (1), N.P. Boldyreva (2), E.I. Ermolenko (2, 3)

1) Pediatric Research and Clinical Center for Infectious Diseases, St. Petersburg, Russia; 2) Institute of Experimental Medicine, St. Petersburg, Russia; 3) St. Petersburg State University, Faculty of Medicine, St. Petersburg, Russia

Background. Campylobacteriosis is one of the most common bacterial intestinal infections worldwide. The high incidence of campylobacteriosis, the clinical diversity of the forms of infection, and the growing resistance of the microorganism to antibiotic therapy largely determine the interest in evaluating the effectiveness of modern approaches to the treatment of campylobacteriosis.
Objective. Assesment of the effects of etiotropic and pathogenetic therapy on the clinical and laboratory parameters of the course of campylobacteriosis in children.
Methods. The study included 90 patients aged 6 months to 17 years with campylobacteriosis. Clinical and laboratory data obtained during inpatient treatment of patients were evaluated. The campylobacterium cultures were isolated from patients; sensitivity of campylobacterium cultures to probiotics and antibacterial drugs was evaluated in vitro.
Results. Campylobacteriosis has been shown to be characterized by a combination of severe intoxication and diarrheal syndromes, accompanied by leukocytosis, an increase in the level of C-reactive protein, and inflammatory events in the coprogram.
Conclusion. In the etiotropic therapy of campylobacteriosis, antibacterial drugs of the macrolide group are most effective. Probiotics significantly inhibit the growth of campylobacter, showing in vitro effects comparable to the use of antibacterial drugs in some cases.


For citations: Ermolenko K.D., Martens E.A., Boldyreva N.P., Ermolenko E.I. Rational therapy for campylobacteriosis in children. Farmateka. 2019;26(10):40–44. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.10.40-44 


About the Autors


Corresponding author: Konstantin D. Ermolenko, PhD, Researcher at the Department of Intestinal Infections, Pediatric Research and Clinical Center for Infectious Diseases, St. Petersburg, Russia; e-mail: ermolenko.kd@yandex.ru
Address: 9, Professor Popov Street, St. Petersburg 197022, Russian Federation


Similar Articles


Бионика Медиа